Clinical trial · Observational
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
NCT01132833CI-TRIAL-00023590completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood in the laboratory from patients receiving chemotherapy may help doctors learn more about the effects of chemotherapy on cells. It may also help doctors understand how patients respond to treatment. PURPOSE: This research study is studying biomarkers related to thrombosis in patients with newly diagnosed multiple myeloma receiving chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Plasma Cell Neoplasm | Plasma Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| enzyme-linked immunosorbent assay | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Levels of circulating tissue factor (TF)
- timeFrame
- 5 years
Secondary outcomes (3)
- measure
- Alteration in coagulation parameters
- timeFrame
- 5 years
- measure
- Correlation of TF with markers of coagulation activation and endothelial activation
- timeFrame
- 5 years
- measure
- Incidence of venous thromboembolism
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Newly diagnosed; relapsed, or refractory multiple myeloma PATIENT CHARACTERISTICS: * Central venous access devices allowed * Recruited by the Division of Hematology/Oncology and the Lineberger Comprehensive Cancer Center at the University of North Carolina * No history of venous thromboembolism * No hospitalization for \> 2 days within the past month * Not pregnant * No patient who refuses or is deemed unsuitable for chemotherapy PRIOR CONCURRENT THERAPY: * No surgery within the past month * Bone marrow biopsies, central venous line placement and diagnostic biopsies by surgery or fine-needle aspiration allowed * \* No concurrent anticoagulation therapy * Concurrent antiplatelet agents, such as aspirin and/or clopidogrel, allowed
References
Publications (0)
Data not yet available
No reference posted for this study.